Cargando…

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies

OBJECTIVE: Previous studies on consumption of caffeine and risk of multiple sclerosis (MS) have yielded inconclusive results. We aimed to investigate whether consumption of coffee is associated with risk of MS. METHODS: Using two population-representative case–control studies (a Swedish study compri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hedström, A K, Mowry, E M, Gianfrancesco, M A, Shao, X, Schaefer, C A, Shen, L, Olsson, T, Barcellos, L F, Alfredsson, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853555/ https://www.ncbi.nlm.nih.gov/pubmed/26940586 http://dx.doi.org/10.1136/jnnp-2015-312176

Ejemplares similares

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study
por: Åkerstedt, Torbjörn, et al.
Publicado: (2023)

Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression
por: Wu, Jing, et al.
Publicado: (2023)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

DRB1–environment interactions in multiple sclerosis etiology: results from two Swedish case–control studies
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
por: Biström, M., et al.
Publicado: (2020)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

T cell composition and polygenic multiple sclerosis risk: A population‐based study in children
por: de Mol, Casper L., et al.
Publicado: (2021)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population
por: de Mol, Casper L., et al.
Publicado: (2022)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Higher‐quality diet and non‐consumption of meat are associated with less self‐determined disability progression in people with multiple sclerosis: A longitudinal cohort study
por: Simpson‐Yap, Steve, et al.
Publicado: (2021)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community
por: Minnema, L. A., et al.
Publicado: (2020)

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
por: Nij Bijvank, Jenny A., et al.
Publicado: (2021)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bfi37j0fkl1sp1jm1m0a005bj7